CO6602160A2 - Terapia de b12 oral - Google Patents

Terapia de b12 oral

Info

Publication number
CO6602160A2
CO6602160A2 CO12159803A CO12159803A CO6602160A2 CO 6602160 A2 CO6602160 A2 CO 6602160A2 CO 12159803 A CO12159803 A CO 12159803A CO 12159803 A CO12159803 A CO 12159803A CO 6602160 A2 CO6602160 A2 CO 6602160A2
Authority
CO
Colombia
Prior art keywords
methods
therapy
oral
patients
levels
Prior art date
Application number
CO12159803A
Other languages
English (en)
Inventor
Cristina Castelli
Original Assignee
Emishpere Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emishpere Technologies Inc filed Critical Emishpere Technologies Inc
Publication of CO6602160A2 publication Critical patent/CO6602160A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Abstract

Se describen métodos para normalizar los niveles de vitamina B12 en pacientes con baja vitamina B12 y métodos para normalizar la variabilidad inter-sujeto en el tratamiento de tales pacientes. También se describen métodos para reducir los niveles de MMA y/o homocisteína, y composiciones farmacéuticas útiles para efectuar tales cambios.
CO12159803A 2010-02-24 2012-09-17 Terapia de b12 oral CO6602160A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30783610P 2010-02-24 2010-02-24

Publications (1)

Publication Number Publication Date
CO6602160A2 true CO6602160A2 (es) 2013-01-18

Family

ID=44477007

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12159803A CO6602160A2 (es) 2010-02-24 2012-09-17 Terapia de b12 oral

Country Status (16)

Country Link
US (3) US20110207693A1 (es)
EP (2) EP2538945A4 (es)
JP (3) JP2013520511A (es)
KR (1) KR20130026429A (es)
AR (1) AR080292A1 (es)
AU (1) AU2011220867B2 (es)
BR (1) BR112012021401B1 (es)
CA (2) CA2996757A1 (es)
CL (1) CL2012002358A1 (es)
CO (1) CO6602160A2 (es)
HK (1) HK1225609A1 (es)
MX (1) MX2012009914A (es)
NZ (2) NZ602032A (es)
RU (1) RU2576511C2 (es)
TW (1) TWI590829B (es)
WO (1) WO2011106378A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357496B2 (en) 2011-11-05 2019-07-23 South Alabama Medical Science Foundation Methods, formulations, and kits for rapidly repleting folate levels in women
TWI829687B (zh) * 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN111517980B (zh) * 2020-05-14 2021-02-09 台州浦凯医药科技有限公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钾晶型化合物、制备方法及用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
AU4484997A (en) * 1996-09-18 1998-04-14 Thomas F. Brennan Compositions containing cobalamin and amino acids
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6117868A (en) * 1998-09-16 2000-09-12 Ed. Geistlich Sohne Ag Fur Chemische Industrie Treatment of gastrointestinal ulcers or gastritis caused by microbial infection
AU4216700A (en) * 1999-04-05 2000-10-23 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
WO2001070219A1 (en) * 2000-03-21 2001-09-27 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides via a dicarboxylate intermediate
US6693094B2 (en) * 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
JP2004526793A (ja) * 2001-04-25 2004-09-02 コバルツ リミテッド 個体における機能性ビタミンｂ１２欠乏症を治療または予防するための方法、およびこの方法に使用するための医療用組成物
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) * 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
AU2003275329B2 (en) * 2002-09-13 2008-04-03 Cydex Pharmaceuticals, Inc. Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
DE10311089A1 (de) * 2003-03-13 2004-09-23 Roche Diagnostics Gmbh Differenzialdiagnostik und Monitoring von Vitamin B12-, Vitamin B6- und Folsäure-Störungen mittels vier unabhängiger Messgrößen
EP1651248B1 (en) * 2003-07-11 2009-09-09 Novartis AG Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
CN102040536B (zh) * 2004-05-06 2013-06-19 爱密斯菲尔科技公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
MX2007001348A (es) * 2004-08-02 2008-03-11 Bebaas Inc Composiciones de vitamina b12.
US20060078622A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
AU2005289685B2 (en) * 2004-09-24 2009-07-16 Amgen Inc. Modified Fc molecules
US20060116334A1 (en) * 2004-12-01 2006-06-01 Curt Hendrix Folate based composition for treatment of the cardiovascular system
JP2009514856A (ja) * 2005-11-04 2009-04-09 ジェンタ インコーポレーテッド 医薬品ガリウム組成物及び方法
BRPI0601834A (pt) * 2006-03-30 2007-11-27 Ricardo De Souza Pereira suplementação dietética para curar ou regredir sintomas de refluxo gastroesofágico, gastrite e úlceras
DE102007005952A1 (de) * 2007-02-06 2008-08-07 BSH Bosch und Siemens Hausgeräte GmbH Kältegerät mit an einer Schiene aufgehängten Fachböden
US7943163B2 (en) * 2007-08-22 2011-05-17 Response Scientific, Inc. Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes
ES2443817T3 (es) * 2007-11-02 2014-02-20 Emisphere Technologies, Inc. Método para tratar la deficiencia de vitamina B12

Also Published As

Publication number Publication date
US20110207693A1 (en) 2011-08-25
NZ602032A (en) 2014-11-28
CA2790708A1 (en) 2011-09-01
HK1225609A1 (zh) 2017-09-15
BR112012021401A2 (pt) 2016-10-25
WO2011106378A3 (en) 2011-11-24
JP2013520511A (ja) 2013-06-06
EP2538945A4 (en) 2013-07-24
CL2012002358A1 (es) 2012-12-14
JP2015193660A (ja) 2015-11-05
TWI590829B (zh) 2017-07-11
MX2012009914A (es) 2013-03-05
AU2011220867A1 (en) 2012-09-20
JP2017101081A (ja) 2017-06-08
TW201200139A (en) 2012-01-01
AU2011220867B2 (en) 2014-05-15
US20160074420A1 (en) 2016-03-17
US20200206247A1 (en) 2020-07-02
RU2576511C2 (ru) 2016-03-10
BR112012021401B1 (pt) 2019-12-24
WO2011106378A2 (en) 2011-09-01
KR20130026429A (ko) 2013-03-13
RU2012136176A (ru) 2014-03-27
AR080292A1 (es) 2012-03-28
EP3028709A1 (en) 2016-06-08
EP3028709B1 (en) 2019-08-28
NZ701274A (en) 2016-03-31
CA2996757A1 (en) 2011-09-01
EP2538945A2 (en) 2013-01-02

Similar Documents

Publication Publication Date Title
IN2012DN06720A (es)
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
EA201500535A1 (ru) Применение akkermansia muciniphila для лечения метаболических расстройств, увеличения расхода энергии и насыщения, снижения веса, композиция, фармацевтическая композиция, косметическая композиция и лекарственное средство
MX2014002668A (es) Tratamiento de enfermedades relacionadas con subunidades alfa de canales de sonido regulados por voltaje (scnxa) con moleculas pequeñas.
CL2014001158A1 (es) Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros.
MY188139A (en) Sodium channel modulators for the treatment of pain
EA201691079A1 (ru) Комбинированная терапия для лечения онкологического заболевания
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
GT201300243A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
AR089993A1 (es) Macrociclos peptidomimeticos
AR075442A1 (es) Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
PH12014502058A1 (en) Pharmaceutical composition comprising empagliflozin and antiobesity drug
BR112014019233A2 (pt) emplastros medicinais para criar ou manter uma área de tecido humano livre de contaminantes
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
BR112015015898A2 (pt) composição farmacêutica de solução sólida
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
GT201500069A (es) Piridinonas bicìclicas novedosas
CL2012002424A1 (es) Método para tratar artitris reumatoide que comprende administrar al paciente laquinimod y metotrexato por vía oral; composición farmacéutica que los comprende.
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
BR112012016543A2 (pt) Tratamento com vb-201
CL2008002747A1 (es) Compuestos derivados de furo y tienopirimidina; composicion farmaceutica; metodo para modular la actividad del receptor de histamina h4; y uso en el tratamiento de trastornos tales como inflamacion, trastornos alergicos, dermatologicos, entre otros.
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
PE20142457A1 (es) Compuestos heterociclicos y sus usos

Legal Events

Date Code Title Description
FC Application refused